Literature DB >> 22749946

Cocaine reverses the naltrexone-induced reduction in operant ethanol self-administration: the effects on immediate-early gene expression in the rat prefrontal cortex.

Víctor Echeverry-Alzate1, María Tuda-Arízcun, Kora-Mareen Bühler, Ángel Santos, Elena Giné, Pedro Olmos, Miguel Ángel Gorriti, Evelio Huertas, Fernando Rodríguez de Fonseca, Jose Antonio López-Moreno.   

Abstract

Naltrexone is a clinically approved medication for alcoholism. We aimed to investigate the effectiveness of naltrexone co-administered with cocaine and the association of these substances with immediate-early gene expression in the rat prefrontal cortex. We used chronic operant ethanol self-administration and oral treatments prescribed for alcoholism and available in pharmacies to maximise the predictive validity in humans. We performed real-time PCR analysis to determine gene expression levels in the prefrontal cortex. Only the highest dose of naltrexone (1, 3, and 10 mg/kg, p.o.) reduced the response to ethanol. Cocaine increased ethanol self-administration in a dose-dependent manner (2.5, 10, 20 mg/kg, i.p.) and reversed the naltrexone-induced reduction. Naltrexone failed to prevent the cocaine-induced increase in locomotor activity observed in these animals. Chronic self-administration of ethanol reduced the expression of the C-fos gene 4- to 12-fold and increased expression of the COX-2 (up to 4-fold) and Homer1a genes in the rat prefrontal cortex. Chronic ethanol self-administration is prevented by naltrexone, but cocaine fully reverses this effect. This result suggests that cocaine may overcome naltrexone's effectiveness as a treatment for alcoholism. The ethanol-induced reduction in C-fos gene expression in the prefrontal cortex reveals an abnormal activity of these neurons, which may be relevant in the compulsive consumption of ethanol, the control of reward-related areas and the behavioural phenotype of ethanol addiction.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22749946     DOI: 10.1016/j.neuropharm.2012.06.010

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Methyl supplementation attenuates cocaine-seeking behaviors and cocaine-induced c-Fos activation in a DNA methylation-dependent manner.

Authors:  Katherine N Wright; Fiona Hollis; Florian Duclot; Amanda M Dossat; Caroline E Strong; T Chase Francis; Roger Mercer; Jian Feng; David M Dietz; Mary Kay Lobo; Eric J Nestler; Mohamed Kabbaj
Journal:  J Neurosci       Date:  2015-06-10       Impact factor: 6.167

2.  Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood.

Authors:  Javier Calleja-Conde; Victor Echeverry-Alzate; Elena Giné; Kora-Mareen Bühler; Roser Nadal; Rafael Maldonado; Fernando Rodríguez de Fonseca; Antoni Gual; Jose Antonio López-Moreno
Journal:  Br J Pharmacol       Date:  2016-07-18       Impact factor: 8.739

3.  Effects of ceftriaxone on GLT1 isoforms, xCT and associated signaling pathways in P rats exposed to ethanol.

Authors:  P S S Rao; Hannah Saternos; Sunil Goodwani; Youssef Sari
Journal:  Psychopharmacology (Berl)       Date:  2015-01-27       Impact factor: 4.530

4.  Effects of topiramate on ethanol-cocaine interactions and DNA methyltransferase gene expression in the rat prefrontal cortex.

Authors:  V Echeverry-Alzate; E Giné; K M Bühler; J Calleja-Conde; P Olmos; M A Gorriti; R Nadal; F Rodríguez de Fonseca; J A López-Moreno
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

5.  Pre-training naltrexone increases conditioned fear learning independent of adolescent alcohol consumption history.

Authors:  Alisa Pajser; Hayley Fisher; Charles L Pickens
Journal:  Physiol Behav       Date:  2020-10-16

Review 6.  Pre-Clinical Studies with D-Penicillamine as a Novel Pharmacological Strategy to Treat Alcoholism: Updated Evidences.

Authors:  Alejandro Orrico; Lucía Martí-Prats; María J Cano-Cebrián; Luis Granero; Ana Polache; Teodoro Zornoza
Journal:  Front Behav Neurosci       Date:  2017-03-07       Impact factor: 3.558

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.